
Richard S Garfein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8935129/publications.pdf Version: 2024-02-01



RICHARD S CAREEIN

#	Article	IF	CITATIONS
1	Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial. Lancet, The, 2012, 379, 1320-1329.	13.7	507
2	Risk of Hepatitis C Virus Infection among Young Adult Injection Drug Users Who Share Injection Equipment. American Journal of Epidemiology, 2002, 155, 645-653.	3.4	393
3	Correlates of Hepatitis C Virus Infections among Injection Drug Users. Medicine (United States), 1995, 74, 212-220.	1.0	350
4	Prevalence and Incidence of Hepatitis C Virus Infection Among Young Adult Injection Drug Users. Journal of Acquired Immune Deficiency Syndromes, 1998, 18, S11-S19.	0.3	307
5	Evaluation of Genetic Mutations Associated with Mycobacterium tuberculosis Resistance to Amikacin, Kanamycin and Capreomycin: A Systematic Review. PLoS ONE, 2012, 7, e33275.	2.5	219
6	Prevalence of Hepatitis C Virus Infection among Injection Drug Users in the United States, 1994–2004. Clinical Infectious Diseases, 2008, 46, 1852-1858.	5.8	174
7	Correlates of HIV infection among young adult short-term injection drug users. Aids, 2000, 14, 717-726.	2.2	168
8	Tuberculosis and Illicit Drug Use: Review and Update. Clinical Infectious Diseases, 2009, 48, 72-82.	5.8	168
9	Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Lancet, The, 2019, 393, 1216-1224.	13.7	156
10	Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 1397-1409.	9.1	147
11	Variability in the Incidence of Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection among Young Injecting Drug Users in New York City. American Journal of Epidemiology, 2003, 157, 467-471.	3.4	134
12	A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. Aids, 2007, 21, 1923-1932.	2.2	131
13	Update and Overview of Practical Epidemiologic Aspects of HIV/AIDS among Injection Drug Users in the United States. Journal of Urban Health, 2006, 83, 86-100.	3.6	119
14	Childhood Sexual Abuse and Age at Initiation of Injection Drug Use. American Journal of Public Health, 2005, 95, 703-709.	2.7	118
15	Problematic use of prescription-type opioids prior to heroin use among young heroin injectors. Substance Abuse and Rehabilitation, 2011, 2, 173.	4.8	116
16	Factors Associated with Adolescent Initiation of Injection Drug Use. Public Health Reports, 2001, 116, 136-145.	2.5	105
17	Predicting Extensively Drug-Resistant Mycobacterium tuberculosis Phenotypes with Genetic Mutations. Journal of Clinical Microbiology, 2014, 52, 781-789.	3.9	99
18	Gender differences in the initiation of injection drug use among young adults. Journal of Urban Health, 2000, 77, 396-414.	3.6	91

#	Article	IF	CITATIONS
19	Evaluation of Three Rapid Screening Assays for Detection of Antibodies to Hepatitis C Virus. Journal of Infectious Diseases, 2011, 204, 825-831.	4.0	89
20	Evaluating the impact of Mexico's drug policy reforms on people who inject drugs in Tijuana, B.C., Mexico, and San Diego, CA, United States: a binational mixed methods research agenda. Harm Reduction Journal, 2014, 11, 4.	3.2	89
21	Screening for Depressive Symptoms Among HCV-Infected Injection Drug Users: Examination of the Utility of the CES-D and the Beck Depression Inventory. Journal of Urban Health, 2004, 81, 278-290.	3.6	88
22	High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug and Alcohol Dependence, 2006, 81, 259-265.	3.2	76
23	Perceived risk, peer influences, and injection partner type predict receptive syringe sharing among young adult injection drug users in five U.S. cities. Drug and Alcohol Dependence, 2007, 91, S18-S29.	3.2	72
24	Methods to recruit and retain a cohort of young-adult injection drug users for the Third Collaborative Injection Drug Users Study/Drug Users Intervention Trial (CIDUS III/DUIT). Drug and Alcohol Dependence, 2007, 91, S4-S17.	3.2	67
25	Monitoring Therapy Adherence of Tuberculosis Patients by using Video-Enabled Electronic Devices. Emerging Infectious Diseases, 2016, 22, 538-540.	4.3	66
26	The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994–2004. Preventive Medicine, 2009, 49, 68-73.	3.4	65
27	Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatology, 2004, 40, 865-873.	7.3	65
28	Digital health for the End TB Strategy: developing priority products and making them work. European Respiratory Journal, 2016, 48, 29-45.	6.7	61
29	Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA. Emerging Infectious Diseases, 2018, 24, 1806-1815.	4.3	60
30	Ethical and regulatory considerations in HIV prevention studies employing respondent-driven sampling. International Journal of Drug Policy, 2009, 20, 14-27.	3.3	58
31	Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.S. Salud Publica De Mexico, 2007, 49, 165-72.	0.4	57
32	Prevalence and correlates of indirect sharing practices among young adult injection drug users in five U.S. cities. Drug and Alcohol Dependence, 2007, 91, S39-S47.	3.2	55
33	Trends in Hepatitis B Virus, Hepatitis C Virus, and Human Immunodeficiency Virus Prevalence, Risk Behaviors, and Preventive Measures among Seattle Injection Drug Users Aged 18–30ÂYears, 1994–2004. Journal of Urban Health, 2007, 84, 436-454.	3.6	54
34	Young adult injection drug users in the United States continue to practice HIV risk behaviors. Drug and Alcohol Dependence, 2009, 104, 167-174.	3.2	53
35	Association between injection practices and duration of injection among recently initiated injection drug users. Drug and Alcohol Dependence, 2004, 75, 177-183.	3.2	52
36	Mortality Risk Among Recent-Onset Injection Drug Users in Five U.S. Cities. Substance Use and Misuse, 2008, 43, 413-428.	1.4	51

#	Article	IF	CITATIONS
37	Evaluation of an HIV Nucleic Acid Testing Program With Automated Internet and Voicemail Systems to Deliver Results. Annals of Internal Medicine, 2010, 152, 778.	3.9	51
38	HIV Transmission Networks in the San Diego–Tijuana Border Region. EBioMedicine, 2015, 2, 1456-1463.	6.1	51
39	Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users. Drug and Alcohol Dependence, 2007, 91, S64-S72.	3.2	50
40	A socio-structural approach to preventing injection drug use initiation: rationale for the PRIMER study. Harm Reduction Journal, 2016, 13, 25.	3.2	50
41	Binge Use and Sex and Drug Use Behaviors among HIV(–), Heterosexual Methamphetamine Users in San Diego. Substance Use and Misuse, 2010, 45, 116-133.	1.4	48
42	Patterns of Drug Use, Risky Behavior, and Health Status Among Persons Who Inject Drugs Living in San Diego, California: A Latent Class Analysis. Substance Use and Misuse, 2015, 50, 205-214.	1.4	48
43	Correlates of attempted suicide among young injection drug users in a multi-site cohort. Drug and Alcohol Dependence, 2004, 75, 261-269.	3.2	47
44	Housing Status and Associated Differences in HIV Risk Behaviors Among Young Injection Drug Users (IDUs). AIDS and Behavior, 2007, 11, 854-863.	2.7	45
45	A Randomized Intervention Trial to Reduce the Lending of Used Injection Equipment Among Injection Drug Users Infected With Hepatitis C. American Journal of Public Health, 2008, 98, 853-861.	2.7	45
46	Association between non-fatal opioid overdose and encounters with healthcare and criminal justice systems: Identifying opportunities for intervention. Drug and Alcohol Dependence, 2015, 153, 215-220.	3.2	43
47	Prevalence, incidence, and correlates of chlamydia and gonorrhea among young adult injection drug users. Journal of Substance Abuse, 2001, 13, 73-88.	1.1	41
48	Eligibility for Treatment of Hepatitis C Virus Infection among Young Injection Drug Users in 3 US Cities. Clinical Infectious Diseases, 2006, 42, 669-672.	5.8	40
49	Sexual Orientation and HIV Infection Prevalence among Young Latino Injection Drug Users in Harlem. Journal of Women's Health and Gender-Based Medicine, 2001, 10, 371-380.	1.5	38
50	Prevalence and Correlates of Heroin–Methamphetamine Co-Injection Among Persons Who Inject Drugs in San Diego, California, and Tijuana, Baja California, Mexico. Journal of Studies on Alcohol and Drugs, 2016, 77, 774-781.	1.0	37
51	Prevalence and correlates of crack-cocaine injection among young injection drug users in the United States, 1997–1999. Drug and Alcohol Dependence, 2005, 77, 227-233.	3.2	36
52	Differences in Sexual Risk Behaviors among Male and Female HIV-Seronegative Heterosexual Methamphetamine Users. American Journal of Drug and Alcohol Abuse, 2009, 35, 295-300.	2.1	36
53	Evaluation of Pyrosequencing for Detecting Extensively Drug-Resistant Mycobacterium tuberculosis among Clinical Isolates from Four High-Burden Countries. Antimicrobial Agents and Chemotherapy, 2015, 59, 414-420.	3.2	36
54	Synchronous and asynchronous video observed therapy (VOT) for tuberculosis treatment adherence monitoring and support. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 17, 100098.	1.3	36

#	Article	IF	CITATIONS
55	Predictors and effects of alcohol use on liver function among young HCV-infected injection drug users in a behavioral intervention. Journal of Hepatology, 2011, 55, 45-52.	3.7	35
56	Tuberculosis, injecting drug use and integrated HIV-TB care: A review of the literature. Drug and Alcohol Dependence, 2013, 129, 180-209.	3.2	35
57	Factors Associated with Patterns of Mobile Technology use among Persons who Inject Drugs. Substance Abuse, 2016, 37, 606-612.	2.3	35
58	Unprotected Sexual Behavior Among Heterosexual HIV-Positive Injection Drug Using Men: Associations by Partner Type and Partner Serostatus. Journal of Urban Health, 2006, 83, 656-668.	3.6	34
59	Performance Comparison of Three Rapid Tests for the Diagnosis of Drug-Resistant Tuberculosis. PLoS ONE, 2015, 10, e0136861.	2.5	34
60	HCV Infection Prevalence Lower Than Expected among 18–40-Year-Old Injection Drug Users in San Diego, CA. Journal of Urban Health, 2013, 90, 516-528.	3.6	33
61	Peer-Education Intervention to Reduce Injection Risk Behaviors Benefits High-Risk Young Injection Drug Users: A Latent Transition Analysis of the CIDUS 3/DUIT Study. AIDS and Behavior, 2013, 17, 2075-2083.	2.7	33
62	Injecting alone among young adult IDUs in five US cities: Evidence of low rates of injection risk behavior. Drug and Alcohol Dependence, 2007, 91, S48-S55.	3.2	32
63	High-Risk Behaviors Associated with Injection Drug Use Among Recently HIV-Infected Men Who Have Sex with Men in San Diego, CA. AIDS and Behavior, 2011, 15, 1561-1569.	2.7	31
64	Requiring smartphone ownership for mHealth interventions: who could be left out?. BMC Public Health, 2020, 20, 81.	2.9	31
65	Pharmacy Participation in Non-Prescription Syringe Sales in Los Angeles and San Francisco Counties, 2007. Journal of Urban Health, 2010, 87, 543-552.	3.6	29
66	Latent Tuberculosis among Persons at Risk for Infection with HIV, Tijuana, Mexico. Emerging Infectious Diseases, 2010, 16, 757-763.	4.3	29
67	The Association between Active and Passive Smoking and Latent Tuberculosis Infection in Adults and Children in the United States: Results from NHANES. PLoS ONE, 2014, 9, e93137.	2.5	29
68	Access to Sterile Syringes through San Francisco Pharmacies and the Association with HIV Risk Behavior among Injection Drug Users. Journal of Urban Health, 2010, 87, 534-542.	3.6	28
69	Video directly observed therapy for supporting and monitoring adherence to tuberculosis treatment in Uganda: a pilot cohort study. ERJ Open Research, 2020, 6, 00175-2019.	2.6	28
70	The Effect of Intimate Partner Violence on Receptive Syringe Sharing Among Young Female Injection Drug Users: An Analysis of Mediation Effects. AIDS and Behavior, 2009, 13, 217-224.	2.7	26
71	Increased Drug Use and STI Risk with Injection Drug Use Among HIV-Seronegative Heterosexual Methamphetamine Users. Journal of Psychoactive Drugs, 2010, 42, 11-18.	1.7	25
72	Use of synthetic cathinones and cannabimimetics among injection drug users in San Diego, California. Drug and Alcohol Dependence, 2014, 141, 99-106.	3.2	25

#	Article	IF	CITATIONS
73	A fragmented code: The moral and structural context for providing assistance with injection drug use initiation in San Diego, USA. International Journal of Drug Policy, 2018, 55, 51-60.	3.3	25
74	Changes in the Sharing of Drug Injection Equipment among Street-Recruited Injection Drug Users in Chicago, Illinois, 1994–1996. Substance Use and Misuse, 2005, 40, 63-76.	1.4	24
75	History of medication-assisted treatment and its association with initiating others into injection drug use in San Diego, CA. Substance Abuse Treatment, Prevention, and Policy, 2017, 12, 42.	2.2	24
76	Primary Incidence of Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men in San Diego, 2000–2015. Open Forum Infectious Diseases, 2019, 6, ofz160.	0.9	24
77	Predictors and correlates of reduced frequency or cessation of injection drug use during a randomized HIV prevention intervention trial. Addiction, 2011, 106, 601-608.	3.3	23
78	Border Crossing to Inject Drugs in Mexico Among Injection Drug Users in San Diego, California. Journal of Immigrant and Minority Health, 2012, 14, 281-286.	1.6	23
79	Differential experiences of Mexican policing by people who inject drugs residing in Tijuana and San Diego. International Journal of Drug Policy, 2017, 41, 132-139.	3.3	23
80	Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study. Lancet Infectious Diseases, The, 2022, 22, 85-96.	9.1	23
81	Comparison of HIV Infection Risk Behaviors Among Injection Drug Users From East and West Coast US Cities. Journal of Urban Health, 2004, 81, 260-267.	3.6	21
82	Design and Feasibility of a Randomized Behavioral Intervention to Reduce Distributive Injection Risk and Improve Health-Care Access Among hepatitisC virus Positive Injection Drug Users: The Study to Reduce Intravenous Exposures (STRIVE). Journal of Urban Health, 2007, 84, 99-115.	3.6	21
83	Hepatitis A and B among young persons who inject drugs—Vaccination, past, and present infection. Vaccine, 2015, 33, 2808-2812.	3.8	21
84	Development, description, and acceptability of a small-group, behavioral intervention to prevent HIV and hepatitis C virus Infections among young adult injection drug users. Drug and Alcohol Dependence, 2007, 91, S73-S80.	3.2	20
85	Latent Tuberculosis Infection in a Migrant Agricultural Community in Baja California, Mexico. Journal of Immigrant and Minority Health, 2011, 13, 940-947.	1.6	19
86	Individual and Socio-Environmental Factors Associated with Unsafe Injection Practices Among Young Adult Injection Drug Users in San Diego. AIDS and Behavior, 2015, 19, 199-210.	2.7	19
87	Increasing Syringe Access and HIV Prevention in California: Findings from a Survey of Local Health Jurisdiction Key Personnel. Journal of Urban Health, 2007, 84, 116-125.	3.6	18
88	Change in Patient Comfort Using Mobile Phones Following the Use of an App to Monitor Tuberculosis Treatment Adherence: Longitudinal Study. JMIR MHealth and UHealth, 2019, 7, e11638.	3.7	18
89	HIV prevalence and sexual risk behaviour among non-injection drug users in Tijuana, Mexico. Global Public Health, 2012, 7, 175-183.	2.0	17
90	MTBDR <i>plus</i> and MTBDR <i>sl</i> Assays: Absence of Wild-Type Probe Hybridization and Implications for Detection of Drug-Resistant Tuberculosis. Journal of Clinical Microbiology, 2016, 54, 912-918.	3.9	17

#	Article	IF	CITATIONS
91	Opioid agonist treatment scale-up and the initiation of injection drug use: A dynamic modeling analysis. PLoS Medicine, 2019, 16, e1002973.	8.4	17
92	The Social and Environmental Context of Cross-Border Drug Use in Mexico: Findings from a Mixed Methods Study of Young Injection Drug Users Living in San Diego, CA. Journal of Ethnicity in Substance Abuse, 2012, 11, 362-378.	0.9	16
93	Feasibility and Acceptability of Cell Phone Diaries to Measure HIV Risk Behavior Among Female Sex Workers. AIDS and Behavior, 2014, 18, 2314-2324.	2.7	16
94	Increased Tuberculosis Patient Mortality Associated with Mycobacterium tuberculosis Mutations Conferring Resistance to Second-Line Antituberculous Drugs. Journal of Clinical Microbiology, 2017, 55, 1928-1937.	3.9	16
95	Potential Risks of Ecological Momentary Assessment Among Persons Who Inject Drugs. Substance Use and Misuse, 2017, 52, 840-847.	1.4	16
96	Potential benefits of using ecological momentary assessment to study high-risk polydrug use. MHealth, 2017, 3, 46-46.	1.6	16
97	Prevalence and correlates of diabetes and metabolic syndrome in a rural indigenous community in Baja California, Mexico. BMC Public Health, 2018, 18, 1397.	2.9	15
98	Gender differences in the provision of injection initiation assistance: a comparison of three North American settings. Harm Reduction Journal, 2018, 15, 59.	3.2	15
99	Three Years after Legalization of Nonprescription Pharmacy Syringe Sales in California: Where Are We Now?. Journal of Urban Health, 2010, 87, 576-585.	3.6	14
100	The impact of the COVID-19 pandemic among migrants in shelters in Tijuana, Baja California, Mexico. BMJ Global Health, 2022, 7, e007202.	4.7	14
101	Prevalence of Diabetes and Metabolic Syndrome in a Migrant Mixtec Population, Baja California, Mexico. Journal of Immigrant and Minority Health, 2013, 15, 93-100.	1.6	13
102	Effect of legal status of pharmacy syringe sales on syringe purchases by persons who inject drugs in San Francisco and San Diego, CA. International Journal of Drug Policy, 2015, 26, 1150-1157.	3.3	13
103	In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence. JAMA Network Open, 2022, 5, e2144210.	5.9	13
104	Hepatitis E Virus among Persons Who Inject Drugs, San Diego, California, USA, 2009–2010. Emerging Infectious Diseases, 2013, 19, 1664-1666.	4.3	12
105	Impact of Fluoroquinolone Use on Mortality Among a Cohort of Patients With Suspected Drug-Resistant Tuberculosis. Clinical Infectious Diseases, 2017, 65, 772-778.	5.8	12
106	Formative Assessment of ARM-U: A Modular Intervention for Decreasing Risk Behaviors Among HIV-Positive and HIV-Negative Methamphetamine-Using MSM. Open AIDS Journal, 2010, 4, 105-115.	0.5	12
107	Prevalence of cryoglobulinemia in hepatitis C virus (HCV) positive patients with and without human immunodeficiency virus (HIV) coinfection. Journal of Clinical Virology, 2004, 31, 210-214.	3.1	11
108	Drug-scene familiarity and exposure to gang violence among residents in a rural farming community in Baja California, Mexico. Global Public Health, 2013, 8, 65-78.	2.0	11

#	Article	IF	CITATIONS
109	Transitions in Latent Classes of Sexual Risk Behavior Among Young Injection Drug Users Following HIV Prevention Intervention. AIDS and Behavior, 2014, 18, 464-472.	2.7	11
110	Awareness of HCV Infection Among Persons Who Inject Drugs in San Diego, California. American Journal of Public Health, 2015, 105, 302-303.	2.7	11
111	Association of Self-Reported Abscess With High-Risk Injection-Related Behaviors Among Young Persons Who Inject Drugs. Journal of the Association of Nurses in AIDS Care, 2019, 30, 142-150.	1.0	11
112	Prevalence and correlates of obstructive lung disease among people who inject drugs, San Diego, California. Drug and Alcohol Dependence, 2020, 214, 108158.	3.2	11
113	The role of gender and power dynamics in injection initiation events within intimate partnerships in the US–Mexico border region. Culture, Health and Sexuality, 2020, 22, 1080-1095.	1.8	10
114	Optimal Testing Choice and Diagnostic Strategies for Latent Tuberculosis Infection Among US-Born People Living with Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 2021, 73, e2278-e2284.	5.8	10
115	Cross-border paid plasma donation among injection drug users in two Mexico–U.S. border cities. International Journal of Drug Policy, 2009, 20, 409-412.	3.3	9
116	Shedding light on the performance of a pyrosequencing assay for drug-resistant tuberculosis diagnosis. BMC Infectious Diseases, 2016, 16, 458.	2.9	9
117	Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California. International Journal of Drug Policy, 2017, 47, 9-17.	3.3	9
118	Identification of a Syndemic of Blood-Borne Disease Transmission and Injection Drug Use Initiation at the US–Mexico Border. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 559-565.	2.1	9
119	A Qualitative Study Exploring Stakeholder Perceptions of Video Directly Observed Therapy for Monitoring Tuberculosis Treatment in the US-Mexico Border Region. Journal of Mobile Technology in Medicine, 2016, 5, 12-23.	0.5	9
120	HIV Infection Risk among Injection Drug Users in a Methadone Maintenance Treatment Program, Taipei, Taiwan 2007–2010. American Journal of Drug and Alcohol Abuse, 2012, 38, 544-550.	2.1	8
121	Trends in Mortality of Tuberculosis Patients in the United States: The Long-Term Perspective. Annals of Epidemiology, 2011, 21, 791-795.	1.9	7
122	Surveillance or support: The experience of direct observation during tuberculosis treatment. Global Public Health, 2018, 13, 804-818.	2.0	7
123	Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis. International Journal of Drug Policy, 2021, 88, 102710.	3.3	7
124	Individual and community factors contributing to anemia among women in rural Baja California, Mexico. PLoS ONE, 2017, 12, e0188590.	2.5	7
125	Impact of SHIELD Police Training on Knowledge of Syringe Possession Laws and Related Arrests in Tijuana, Mexico. American Journal of Public Health, 2022, 112, 860-864.	2.7	7
126	Cigarette Smoking and Quit Attempts Among Injection Drug Users in Tijuana, Mexico. Nicotine and Tobacco Research, 2013, 15, 2060-2068.	2.6	6

#	Article	IF	CITATIONS
127	Cost analysis of rapid diagnostics for drug-resistant tuberculosis. BMC Infectious Diseases, 2018, 18, 102.	2.9	6
128	Municipal police support for harm reduction services in officer-led referrals of people who inject drugs in Tijuana, Mexico. Harm Reduction Journal, 2021, 18, 76.	3.2	6
129	High Tuberculosis Treatment Adherence Obtained Using Mobile Phones for Video Directly Observed Therapy: Results of a Binational Pilot Study. Journal of Mobile Technology in Medicine, 2012, 1, 30-30.	0.5	6
130	Deportation History Among HIV-Positive Latinos in Two US–Mexico Border Communities. Journal of Immigrant and Minority Health, 2015, 17, 104-111.	1.6	5
131	Decreased Anemia Prevalence Among Women and Children in Rural Baja California, Mexico: A 6-Year Comparative Study. Journal of Community Health, 2016, 41, 780-789.	3.8	5
132	Correlates of perceived risk of HIV infection among persons who inject drugs in Tijuana,Baja California, Mexico. Salud Publica De Mexico, 2015, 57, 107.	0.4	5
133	Comparison of Three Popular Methods for Recruiting Young Persons Who Inject Drugs for Interventional Studies. Journal of Urban Health, 2017, 94, 587-591.	3.6	4
134	Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar. BMJ Global Health, 2021, 6, e004181.	4.7	4
135	Costâ€effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico. Addiction, 2021, 116, 2734-2745.	3.3	4
136	Content and Design of Laboratory Report Forms for Human Immunodeficiency Virus Type 1 Antibody Testing. American Journal of Clinical Pathology, 1992, 98, 199-204.	0.7	3
137	Evaluating a Statewide Pilot Syringe Access Program for Injection Drug Users through Pharmacies in California. Journal of Urban Health, 2010, 87, 531-533.	3.6	3
138	Prevalence and Correlates of the Use of Prefilled Syringes Among Persons Who Inject Drugs in San Diego, CA. Journal of Urban Health, 2015, 92, 1081-1091.	3.6	3
139	Cold Preparation of Heroin in a Black Tar Market. Substance Use and Misuse, 2017, 52, 1242-1246.	1.4	3
140	Prevalence and Correlates of Injecting with Visitors from the United States Among People Who Inject Drugs in Tijuana, Mexico. Journal of Immigrant and Minority Health, 2019, 21, 1200-1207.	1.6	3
141	Selfâ€perception of assisting with future injection drug initiation: The influence of relationships in the process of drug injecting initiation. Drug and Alcohol Review, 2021, 40, 109-117.	2.1	3
142	Involvement of people who inject drugs in injection initiation events: a cross-sectional analysis identifying similarities and differences across three North American settings. BMJ Open, 2021, 11, e046957.	1.9	3
143	Tuberculosis testing among populations with high HIV risk in Tijuana, Baja California, Mexico. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2012, 32, 30-35.	1.1	3
144	Management and control of tuberculosis control in socially complex groups: a research programme including three RCTs. Programme Grants for Applied Research, 2020, 8, 1-76.	1.0	3

#	Article	IF	CITATIONS
145	RE: "HIGH RATES OF HIV INFECTION AMONG INJECTION DRUG USERS PARTICIPATING IN NEEDLE EXCHANGE PROGRAMS IN MONTREAL: RESULTS OF A COHORT STUDY". American Journal of Epidemiology, 1999, 150, 325-325.	3.4	2
146	Latent Tuberculosis Screening Using Electronic Health Record Data. Emerging Infectious Diseases, 2020, 26, 2285-2287.	4.3	2
147	Cell phone access among persons who inject drugs in Tijuana, BC, Mexico. Journal of Mobile Technology in Medicine, 2015, 4, 13-19.	0.5	2
148	Knowledge, Attitude, Practices, and Vaccine Hesitancy Among the Latinx Community in Southern California Early in the COVID-19 Pandemic: Cross-sectional Survey. JMIR Formative Research, 2022, 6, e38351.	1.4	2
149	Cash transfer scheme for reducing HIV and herpes simplex type 2 – Authors' reply. Lancet, The, 2012, 380, 802-803.	13.7	1
150	Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility forMycobacterium tuberculosis. European Respiratory Journal, 2017, 49, 1602215.	6.7	1
151	Formative Assessment of ARM-U: A Modular Intervention for Decreasing Risk Behaviors Among HIV-Positive and HIV-Negative Methamphetamine- Using MSM. Open AIDS Journal, 2010, 4, 105-115.	0.5	1
152	An important, but not the first, hepatitis C virus behavioural intervention study: authors' reply. Aids, 2008, 22, 320.	2.2	0
153	Identifying COVID-19 Cases and Social Groups at High Risk of Transmission: A Strategy to Reduce Community Spread. Public Health Reports, 2021, 136, 259-263.	2.5	0
154	Discordant results of tests for tuberculosis reconsidered – Authors' reply. Lancet Infectious Diseases, The, 2022, 22, 164-165.	9.1	0